UK Expands IMCIVREE Approval to Acquired Hypothalamic Obesity
RYTM sits 50% above its 52-week low of $74.5.
Summary
Rhythm Pharmaceuticals secured expanded UK marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in patients with acquired hypothalamic obesity due to hypothalamic injury or impairment. This opens a new patient population beyond the drug's existing rare genetic obesity indications. The approval follows positive Phase 2 data in acquired hypothalamic obesity reported earlier this month, reinforcing the drug's clinical profile. The UK decision could signal a path for broader European adoption and strengthens the commercial opportunity for IMCIVREE. With Q2 2026 revenue already showing 19% sequential growth, this label expansion adds a meaningful new revenue stream.
At the time of this announcement, RYTM was trading at $111.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.